Rituximab-induced severe acute thrombocytopenia in a patient with splenic marginal zone lymphoma

Basit Öğe Kaydı
dc.contributor.authorKars, Taha Ulutan
dc.contributor.authorYorganci, Zahit Furkan
dc.contributor.authorYaskiran, Osman
dc.contributor.authorTekinalp, Atakan
dc.contributor.authorDemircioglu, Sinan
dc.date.accessioned2024-02-23T14:27:03Z
dc.date.available2024-02-23T14:27:03Z
dc.date.issued2023
dc.departmentNEÜen_US
dc.description.abstractIntroduction Rituximab, which is widely used in the treatment of B-cell lymphoma, is a chimeric monoclonal antibody directed against the CD20 antigen. Rituximab has many side effects, mainly allergic and neurological. Rituximab may cause thrombocytopenia in the long term after administration. Rare cases of rituximab-induced acute thrombocytopenia have been reported in the literature. Case Report A 51-year-old female patient who was newly diagnosed with splenic marginal zone lymphoma received rituximab as first-line therapy. Petechiae occurred in the lower extremities on the day following rituximab administration. The blood test showed a severe drop in the platelet count from 112,000/mu L to 5000/mu L. Blood peripheral smear evaluation confirmed severe thrombocytopenia. Management and outcome There was no change in hemoglobin or white blood cell levels. After the diagnosis of rituximab-induced acute thrombocytopenia, thrombocyte suspension was administered due to the risk of bleeding. Close clinical and laboratory observations were made. The platelet count began to rise gradually in the following period. Before the second week of rituximab administration, the platelet count was 122,000/mu L. No complications developed after premedication and slow rituximab administration, and subsequent treatments were continued in the same way. Discussion Rituximab has widespread use, especially in malignancies and autoimmune diseases. Like many monoclonal antibodies, rituximab has several side effects. Thrombocytopenia is a long-term side effect associated with rituximab, and rituximab-induced severe acute thrombocytopenia has been rarely reported. Therefore, it should be kept in mind that severe acute thrombocytopenia may develop after rituximab administration.en_US
dc.identifier.doi10.1177/10781552221142870
dc.identifier.endpage1014en_US
dc.identifier.issn1078-1552
dc.identifier.issn1477-092X
dc.identifier.issue4en_US
dc.identifier.pmid36458320en_US
dc.identifier.scopus2-s2.0-85143613112en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1011en_US
dc.identifier.urihttps://doi.org/10.1177/10781552221142870
dc.identifier.urihttps://hdl.handle.net/20.500.12452/14431
dc.identifier.volume29en_US
dc.identifier.wosWOS:000893177600001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofJournal Of Oncology Pharmacy Practiceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectRituximaben_US
dc.subjectAcute Thrombocytopeniaen_US
dc.subjectSplenic Marginal Zone Lymphomaen_US
dc.titleRituximab-induced severe acute thrombocytopenia in a patient with splenic marginal zone lymphomaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu